Poseida Therapeutics

The CRISPR and Cas gene market was valued at $3.3 billion in 2023, with a CAGR of 20.38% since 2018. It's projected to reach $8.8 billion by 2028 and $24.6 billion by 2033. Growth drivers include personalized medicine, genetic disorders, and synthetic biology. Challenges include regulatory complexities and healthcare access in developing countries. The market is segmented by type, application, product type, end use, and service type, with various segments showing significant growth potential. North America leads the market, but Asia-Pacific and Africa are expected to grow fastest. The market is dominated by large players like Danaher Corporation and Agilent Technologies Inc.

The FDA investigates bluebird bio's Skysona over hematologic malignancies. REGENXBIO starts phase 3 AFFINITY DUCHENNE trial for RGX-202 in DMD. Genethon and Hansa Biopharma initiate phase 2 trial for Crigler–Najjar syndrome. Sana Biotechnology's SC291 gets fast track designation for SLE. Roche to acquire Poseida Therapeutics. Exegenesis Bio's EXG110 receives orphan drug designation for Fabry disease. NorthX Biologics partners with Amarna Therapeutics for Nimvec AM510.

Episode 7 of 'Behind the Headlines' discusses the UK measles outbreak, mRNA conferences, and Roche's acquisition of Poseida Therapeutics for $1.5 billion.

Roche to acquire Poseida Therapeutics for $1 billion, with potential for up to $1.5 billion based on milestones, gaining access to allogeneic CAR T-cell therapies for oncology, immunology, and autoimmune diseases. The deal includes Poseida's P-BCMA-ALLO1 for multiple myeloma and P-CD19CD20-ALLO1 for B-cell malignancies and autoimmune diseases, along with GMP manufacturing capabilities and genomic medicine assets.

Black Friday sale offers 20% off The Scenarionist Premium Annual Plan. Deep Tech Briefing #40 covers AI policy, startup funding, eVTOL sector challenges, AI standards, space tech advancements, protein AI innovation, energy scaling issues, and quantum computing progress.

Roche acquires Poseida Therapeutics for up to $1.5B, expanding into CAR-T therapies. U.S. overdose deaths decline by 14.5% to 97,000 over 12 months. Arrowhead Pharmaceuticals licenses programs to Sarepta Therapeutics for $500M upfront and $325M in equity. Recordati and Angelini Pharma consider merger to form Europe's largest generics group. FDA approves BridgeBio's heart drug for transthyretin amyloidosis, challenging Pfizer's tafamidis. Novo Holdings expected to receive EU approval for $16.5B acquisition of Catalent Pharma Solutions. Amgen's obesity drug MariTide shows 20% weight loss in Phase II. Anavex Life Sciences submits MAA to EMA for Alzheimer's treatment. Biohaven's muscle drug fails in SMA study. embecta reports strong revenues of $1.12B, discontinues insulin patch pump. Axsome Therapeutics reports positive Phase 3 results for narcolepsy drug AXS-12. Kronos Bio to lay off 83% of workforce. PTC Therapeutics sells Rare Pediatric Disease Priority Review Voucher for $150M. EMA launches medicine shortages monitoring platform. Alector lays off 41 employees after Alzheimer's drug AL002 fails. Grifols seeks to refinance €1.4B in debt. Roche's cancer drug tiragolumab fails Phase 3 trial.

Roche to acquire Poseida Therapeutics, gaining GMP manufacturing capabilities and R&D assets, focusing on allogeneic CAR-T cell therapies for oncology, immunology, and neurology. The $1 billion deal, expected to close Q1 2025, builds on their 2022 strategic partnership.

Roche to acquire Poseida Therapeutics for $1 billion. Merck, AstraZeneca, and Novartis see success in new drug studies. Novartis' Kisqali approved for broader breast cancer treatment in EU.